|
|
| | N-(4-fluoro-2-Methoxy-5-nitrophenyl)-4-(1-Methylindol-3-yl)pyriMidin-2-aMine Basic information |
| Product Name: | N-(4-fluoro-2-Methoxy-5-nitrophenyl)-4-(1-Methylindol-3-yl)pyriMidin-2-aMine | | Synonyms: | N-(4-fluoro-2-Methoxy-5-nitrophenyl)-4-(1-Methylindol-3-yl)pyriMidin-2-aMine;2-PyriMidinaMine, N-(4-fluoro-2-Methoxy-5-nitrophenyl)-4-(1-Methyl-1H-indol-3-yl)-;(4-Fluoro-2-methoxy-5-nitro-phenyl)-[4-(1-methyl-1h-indol-3-yl)-pyrimidin-2-yl]-amine;AZD9291 1;OSIMERTINIB INTERMEDIATE 1;N-(4-fluoro-2-methoxy-5-nitrophenyl)-
4-(1-methylindol-3-yl)pyrimidin-2-amine(AZD9291 Intermediate 2);EOS-61221;N-(4-Fluoro-2-methoxy-5-nitrophenyl)-4-(1-methyl-3-indolyl)-2-pyrimidinamine | | CAS: | 1421372-94-2 | | MF: | C20H16FN5O3 | | MW: | 393.37 | | EINECS: | 806-156-3 | | Product Categories: | AZD9291;1421372-94-2 | | Mol File: | 1421372-94-2.mol |  |
| | N-(4-fluoro-2-Methoxy-5-nitrophenyl)-4-(1-Methylindol-3-yl)pyriMidin-2-aMine Chemical Properties |
| Melting point | >250°C (dec.) | | Boiling point | 639.3±65.0 °C(Predicted) | | density | 1.41±0.1 g/cm3(Predicted) | | storage temp. | 2-8°C(protect from light) | | solubility | DMSO (Slightly, Heated) | | pka | 2.02±0.10(Predicted) | | form | Solid | | color | Light Yellow to Yellow | | InChI | InChI=1S/C20H16FN5O3/c1-25-11-13(12-5-3-4-6-17(12)25)15-7-8-22-20(23-15)24-16-10-18(26(27)28)14(21)9-19(16)29-2/h3-11H,1-2H3,(H,22,23,24) | | InChIKey | SZTYQQYYIMVETL-UHFFFAOYSA-N | | SMILES | C1(NC2=CC([N+]([O-])=O)=C(F)C=C2OC)=NC=CC(C2C3=C(N(C)C=2)C=CC=C3)=N1 |
| | N-(4-fluoro-2-Methoxy-5-nitrophenyl)-4-(1-Methylindol-3-yl)pyriMidin-2-aMine Usage And Synthesis |
| Uses | N-(4-Fluoro-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H-indol-3-yl)-2-pyrimidinamine functions as a reagent in the synthesis of dihydropyrroloquinoline derivatives with anticancer activity as EGFR modulator to inhibit L858R/T790M. | | Pharmaceutical Applications | N-(4-fluoro-2-Methoxy-5-nitrophenyl)-4-(1-Methylindol-3-yl)pyriMidin-2-aMine is a intermediate of Osimertinib in the treatment of non-small cell lung cancer. | | Synthesis | To a 2L three-necked flask was added 1000 mL of 2-pentanol, 50 g of 3-(2-chloropyrimidin-4-yl)-1-methylindole, 42 g of 4-fluoro-2-methoxy-5-nitroaniline, and 3.54 g of p-toluenesulfonic acid at room temperature. The reaction mixture was heated to 80 °C and kept stirring for 6 hours. Upon completion of the reaction, the mixture was cooled to 25 °C to 28 °C, followed by filtration to collect the solid product. The filter cake was washed with preheated 2-pentanol (50 °C) to remove impurities. The resulting solid product was dried in a vacuum oven to give 80.1 g of the final yellow solid product N-(4-fluoro-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-amine in 99.0% yield. | | References | [1] Patent: CN107188888, 2017, A. Location in patent: Paragraph 0061-0063
[2] European Journal of Medicinal Chemistry, 2017, vol. 135, p. 12 - 23
[3] Patent: WO2013/14448, 2013, A1. Location in patent: Page/Page column 138
[4] Journal of Medicinal Chemistry, 2014, vol. 57, # 20, p. 8249 - 8267
[5] Patent: CN107043369, 2017, A. Location in patent: Paragraph 0395; 0396; 0397; 0398 |
| | N-(4-fluoro-2-Methoxy-5-nitrophenyl)-4-(1-Methylindol-3-yl)pyriMidin-2-aMine Preparation Products And Raw materials |
|